Literature DB >> 2859303

Verotoxin and neuraminidase induced platelet aggregating activity in plasma: their possible role in the pathogenesis of the haemolytic uraemic syndrome.

P E Rose, J A Armour, C E Williams, F G Hill.   

Abstract

Certain strains of Escherichia coli producing verotoxin have been isolated in the stools of patients with the haemolytic uraemic syndrome. A platelet aggregating activity has been found in normal plasma after incubation with verotoxin at 37 degrees C for 24 h. This activity, unlike neuraminidase, has an effect that is independent of changing factor VIII related antigen, but requires the IIA and IIIB platelet surface glycoprotein (deficient in thrombasthenia) to mediate its effect. Prostacyclin totally inhibited this effect, but other antiplatelet drugs and heparin were without inhibitory effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859303      PMCID: PMC499173          DOI: 10.1136/jcp.38.4.438

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities.

Authors:  P N Walsh
Journal:  Br J Haematol       Date:  1972-02       Impact factor: 6.998

Review 2.  Hemolytic-uremic syndrome. Current concepts and management.

Authors:  J S Fong; J P de Chadarevian; B S Kaplan
Journal:  Pediatr Clin North Am       Date:  1982-08       Impact factor: 3.278

Review 3.  The role of increased platelet aggregation in TTP.

Authors:  E C Lian
Journal:  Semin Thromb Hemost       Date:  1980       Impact factor: 4.180

4.  Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets.

Authors:  J Hawiger; S Parkinson; S Timmons
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

5.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

6.  Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?

Authors:  G Remuzzi; R Misiani; D Marchesi; M Livio; G Mecca; G de Gaetano; M B Donati
Journal:  Lancet       Date:  1978-10-21       Impact factor: 79.321

7.  Prostacyclin (PGI2) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity.

Authors:  M L Ehrman; E A Jaffe
Journal:  Prostaglandins       Date:  1980-12

8.  Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli.

Authors:  A D O'Brien; G D LaVeck; M R Thompson; S B Formal
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

9.  Subunit structure of Shigella cytotoxin.

Authors:  S Olsnes; R Reisbig; K Eiklid
Journal:  J Biol Chem       Date:  1981-08-25       Impact factor: 5.157

10.  Pathogenesis of Shigella diarrhea. VII. Evidence for a cell membrane toxin receptor involving beta1 leads to 4-linked N-acetyl-D-glucosamine oligomers.

Authors:  G T Keusch; M Jacewicz
Journal:  J Exp Med       Date:  1977-08-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Platelet-bacterial interactions.

Authors:  Steven W Kerrigan; Dermot Cox
Journal:  Cell Mol Life Sci       Date:  2009-11-29       Impact factor: 9.261

Review 2.  Pathogenesis of the hemolytic uremic syndromes: current concepts.

Authors:  B S Kaplan; V V Vedaranayanan
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

Review 3.  Causes of the haemolytic uraemic syndrome.

Authors:  J Kavi; R Wise
Journal:  BMJ       Date:  1989-01-14

4.  Clinical and pathological variability of infection by enterohaemorrhagic (Vero cytotoxin producing) Escherichia coli.

Authors:  C M Hunt; J A Harvey; E R Youngs; S T Irwin; T M Reid
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

5.  Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands.

Authors:  C M Taylor; R H White; M H Winterborn; B Rowe
Journal:  Br Med J (Clin Res Ed)       Date:  1986-06-07

6.  Classification of haemolytic uraemic syndrome.

Authors:  R P Cooke; P E Rose
Journal:  J Clin Pathol       Date:  1986-07       Impact factor: 3.411

Review 7.  Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.

Authors:  Carla Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2010-04-28       Impact factor: 3.714

8.  Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.

Authors:  L L Cooling; K E Walker; T Gille; T A Koerner
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Thromboembolism in inflammatory bowel disease: role of platelets.

Authors:  M J Webberley; M T Hart; V Melikian
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

10.  Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia.

Authors:  Ya-Lan Guo; Dan-Qing Liu; Zhen Bian; Chen-Yu Zhang; Ke Zen
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.